SYSMEX INOSTICS INC.

Company Overview

Sysmex Inostics GmbH, a subsidiary of Sysmex Corp., is developing and commercializing liquid biopsy-based molecular diagnostics using digital PCR and plasma-sequencing technologies. The main focus is on analyzing circulating tumor DNA (ctDNA) for cancer-related mutations. The company operates a CLIA-certified laboratory in the United States.

Sysmex products and services include biopharma testing, clinical testing and kit products. Clinical testing services are offered in the United States and include OncoBEAM liquid biopsy for lung cancer, colorectal cancer and melanoma.

The OncoBEAM platform analyzes ctDNA fragments that are circulating in the blood using digital PCR, magnetic beads and flow cytometry.

The SafeSeq platform uses NGS together with proprietary bioinformatic analysis and is compatible with either tissue samples or plasma ctDNA.

In April 2023, Sysmex partnered with Genomic Testing Cooperative (GTC) to commercialize GTC’s solid tumor and hematology assay services for biopharma customers. The collaboration includes GTC’s Solid Tumor Profile Plus, Liquid Trace Solid Tumor Profile, Liquid Trace Hematology Profile, and Hematology Profile Plus assay services.

Company's Business Segments

• Products : Broad Panel Assays, Targeted Panel Assays, cfHPV DNA Assay.
• Services : Ultra-sensitive assay capabilities, Plasma-SeqSensei Kits.